1. Ohayon MM, Hong SC. Prevalence of insomnia and associated factors in South Korea. J Psychosom Res 2002;53:593–600.
2. Bertolote JM, Fleischmann A, De Leo D, Wasserman D. Psychiatric diagnoses and suicide: revisiting the evidence. Crisis 2004;25:147–155.
3. Kales JD, Kales A, Bixler EO, et al. Biopsychobehavioral correlates of insomnia, V: clinical characteristics and behavioral correlates. Am J Psychiatry 1984;141:1371–1376.
4. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97–111.
5. Berry RB, Harding SM. Sleep and medical disorders. Med Clin North Am 2004;88:679–703.
6. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update: an American academy of sleep medicine report. Sleep 2006;29:1415–1419.
7. Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA, Lichstein KL. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep 2006;29:1398–1414.
8. Zhdanova IV. Advances in the management of insomnia. Expert Opin Pharmacother 2004;5:1573–1579.
9. Kim SJ. Pharmacotherapy of insomnia. J Korean Med Assoc 2009;52:719–726.
10. Kim L. Stress, sleep physiology, and related insomnia disorders. J Korean Med Assoc 2010;53:707–716.
11. Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990;40:291–313.
12. Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system side effects associated with zolpidem treatment. Clin Neuropharmacol 2000;23:54–58.
13. Brodeur MR, Stirling AL. Delirium associated with zolpidem. Ann Pharmacother 2001;35:1562–1564.
14. Freudenreich O, Menza M. Zolpidem-related delirium: a case report. J Clin Psychiatry 2000;61:449–450.
16. Yang W, Dollear M, Muthukrishnan SR. One rare side effect of zolpidem: sleepwalking: a case report. Arch Phys Med Rehabil 2005;86:1265–1266.
17. Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002;3:323–327.
18. Siddiqui F, Osuna E, Chokroverty S. Writing emails as part of sleepwalking after increase in Zolpidem. Sleep Med 2009;10:262–264.
20. Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry 2003;25:345–352.
21. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995;29:142–153.
23. Pies RW. Dose-related sensory distortions with zolpidem. J Clin Psychiatry 1995;56:35–36.
24. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231–237.
25. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983;140:1048–1050.
26. Pompei P, Foreman M, Cassel CK, Alessi C, Cox D. Detecting delirium among hospitalized older patients. Arch Intern Med 1995;155:301–307.
27. Lipowski ZJ. Delirium: Acute Confusional States. New York: Oxford University Press, 1992:115:1242–1243.
28. Breitbart W, Strout D. Delirium in the terminally ill. Clin Geriatr Med 2000;16:357–372.